Alkem Laboratories Ltd logo

Alkem Laboratories Ltd

ALKEM NSE

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
₹65,474 Cr
Volatility
Moderate
P/E Ratio
30.34
EBITDA
₹3,589 Cr
Return on Equity
16.4%
Debt to Equity
0.15
Book Value
₹1,155.87
EPS
₹179.8
52W High
₹5,933.5
52W Low
₹5,075

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Alkem Laboratories Ltd insights

68 extracted metrics + investor summaries across FY09–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 26.3%

Weaknesses

2
  • Promoter holding has decreased over last quarter: -1.50%
  • The company has delivered a poor sales growth of 10.7% over past five years.

Growth Rate

Revenue Growth
13.65% ↗
Net Income Growth
6.19% ↘
Cash Flow Change
2.62% ↗
ROE
-7.97% ↘
ROCE
-2.33% ↘
EBITDA Margin (Avg.)
5.06% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk medium

Alkem Laboratories trades at a market cap of ₹64,798 Cr with a P/E of 27.8x. FY25 revenue stood at ₹12,965 Cr (up 2.3% YoY) with EBITDA margins expanding from 17.7% to 19.4%, while the company has delivered a 3-year profit CAGR of 32% driven by margin recovery after a weak FY23. The India business (69% of sales) continues to grow steadily but international sales have been volatile.

Bull Case 8
  • Strong 3-year compounded profit growth of 32% CAGR, indicating significant earnings recovery and margin expansion
  • EBITDA margin expanded from 17.7% in FY24 to 19.4% in FY25, a 170 bps improvement reflecting cost optimization
  • Consistent ROE of 18-19% over 3, 5, and 10-year periods demonstrates efficient capital allocation
  • India domestic business contributes 68.7% of revenue and grew 6% YoY in 9M FY25, providing stability from a large addressable market
  • 18 brands feature in the Top 300 brands in the Indian Pharmaceutical Market with leadership in anti-infectives segment
  • Trade generics segment accounts for ~20% of domestic business and is growing at 14-15% annually, offering diversification
  • Chronic therapy segment now contributes approximately 18% of total prescription portfolio, indicating successful pivot toward higher-margin therapies
  • Healthy dividend payout ratio of 26.3% with a current yield of 0.97%, providing income return to shareholders
Bear Case 8
  • FY25 revenue growth was only 2.3% YoY (₹12,965 Cr vs ₹12,673 Cr), sharply below the 10-year sales CAGR of 12%
  • International sales declined 7.7% YoY in the first nine months of FY25 (₹28,463 Mn vs ₹30,837 Mn), reflecting US pricing pressure
  • P/E of 27.8x is elevated relative to the 5-year compounded profit CAGR of only 9%, implying limited margin of safety
  • Promoter holding decreased by 1.50% in the last quarter, signaling potential insider caution
  • 5-year compounded sales growth of only 10.7-11% is below the broader Indian pharma sector average, indicating market share challenges
  • Stock price CAGR of just 2% over 1 year and 8% over 5 years has significantly underperformed the broader market
  • P/B ratio of 4.73x is rich for a company with sub-20% ROE, limiting valuation re-rating potential
  • Q4 FY25 EBITDA margin of 12.4% was below Q4 FY24's 13.7%, showing quarterly margin volatility despite annual improvement

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 5h ago
Headwinds 1
  • Senior VP resignation Jul 23

    Dr. Jitendra Singh Huda resigned as Senior VP effective July 23, 2026, to pursue other professional opportunities, creating a leadership gap in the organization.

Positives 5
  • Q1FY27 profit surges 48% YoY Jul 30

    Standalone net profit jumped 48% YoY to ₹432.10 crore in Q1FY27, driven by a 25% revenue surge to ₹3,444.70 crore.

  • Adroit Biomed merger approved Aug 17

    Equity shareholders approved the amalgamation with Adroit Biomed Limited with 99.9999% votes in favour, clearing a key corporate restructuring milestone.

  • ₹75 crore Baddi expansion Aug 14

    Board approved up to ₹75 crore investment for a new manufacturing block at the existing Baddi, Himachal Pradesh facility to enhance domestic capacity.

  • New SVP Marketing & Sales Aug 3

    Rajpal Singh Rana appointed as SVP - Marketing & Sales effective August 3, 2026, bringing 30+ years of pharma sector experience.

  • GHG emissions cut 15% in FY26 Jul 29

    Scope 1 and 2 GHG emissions reduced 15% in FY26, energy consumption dropped 22%, and 4,376 MT of plastic waste was recycled.

Neutral 2
  • Trading window opens Aug 17 Aug 14

    Trading window opened on August 17, 2026, following communication of Q1FY27 financial results to stock exchanges.

  • Q1FY27 earnings call scheduled Jul 27

    Conference call held August 14, 2026 at 4:30 PM IST hosted by Motilal Oswal Securities to discuss Q1FY27 results.

TL;DR: Alkem Laboratories is delivering strong operational momentum with Q1FY27 profit up 48% YoY on robust revenue growth, complemented by capacity expansion and a successful merger approval. ESG improvements and leadership additions further strengthen the outlook. The only minor concern is a senior VP departure, which is already being addressed with new appointments. The trend is clearly improving with growth investments and earnings acceleration pointing to continued strength in coming quarters.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
2,968
3,440
3,324
2,936
3,032
3,415
3,374
3,144
3,371
4,001
3,737
3,603
3,740
Expenses
2,579
2,693
2,616
2,534
2,423
2,662
2,615
2,752
2,632
3,080
2,909
3,086
2,974
Operating Profit
389
747
708
402
609
753
759
391
739
921
828
517
766
OPM %
13%
22%
21%
14%
20%
22%
23%
12%
22%
23%
22%
14%
20%
Other Income
66
6
42
76
120
134
93
146
149
104
90
65
153
Interest
30
30
25
27
29
28
36
28
30
35
42
54
47
Depreciation
72
74
70
83
80
79
85
112
88
94
95
106
100
PBT
353
648
655
367
619
780
731
396
771
896
781
423
772
Tax %
18%
5%
8%
17%
11%
10%
12%
18%
13%
13%
16%
40%
32%
Net Profit
288
615
604
304
550
702
641
322
668
779
653
251
521
EPS in Rs
23.98
51.9
49.76
24.55
45.6
57.6
52.34
25.58
55.56
63.99
53.19
19.78
43.49
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3,674
4,905
5,688
6,401
7,357
8,344
8,865
10,634
11,599
12,668
12,965
14,712
15,081
Expenses
3,248
4,038
4,687
5,392
6,237
6,868
6,920
8,580
9,977
10,419
10,452
11,706
12,049
Operating Profit
427
866
1,001
1,009
1,120
1,476
1,945
2,054
1,622
2,249
2,512
3,007
3,032
OPM %
12%
18%
18%
16%
15%
18%
22%
19%
14%
18%
19%
20%
20%
Other Income
176
227
110
115
82
102
230
146
101
186
494
407
412
Interest
81
71
45
55
55
65
59
52
107
112
122
161
178
Depreciation
71
93
101
143
193
253
275
304
310
299
357
382
395
PBT
451
928
965
926
955
1,260
1,842
1,844
1,305
2,023
2,527
2,871
2,872
Tax %
13%
19%
6%
31%
19%
9%
12%
9%
23%
10%
12%
18%
—
Net Profit
392
752
905
638
774
1,149
1,618
1,680
1,007
1,811
2,215
2,351
2,204
EPS in Rs
32.75
62.02
74.61
52.77
63.61
94.26
133
138
82.31
150
181
193
180
Div. Payout %
12%
20%
20%
25%
25%
27%
23%
25%
61%
27%
25%
28%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
24
24
24
24
24
24
24
24
24
24
24
24
Reserves
2,975
3,668
4,444
4,840
5,415
6,137
7,353
8,614
9,021
10,288
11,961
13,796
Borrowings
1,306
658
659
998
944
1,616
1,707
2,668
1,397
1,418
1,381
2,047
Other Liabilities
986
1,184
1,440
1,803
1,824
2,169
2,435
2,763
3,315
3,844
4,325
4,991
Total Liabilities
5,291
5,534
6,568
7,664
8,208
9,946
11,519
14,069
13,757
15,575
17,691
20,858
Fixed Assets
1,374
1,450
1,797
2,284
2,530
2,908
2,793
2,902
2,683
2,873
2,852
3,871
CWIP
111
172
299
381
493
363
393
339
323
159
548
282
Investments
481
509
553
444
324
261
333
371
622
484
1,846
1,869
Other Assets
3,325
3,403
3,918
4,555
4,861
6,413
8,000
10,457
10,129
12,060
12,445
14,836
Total Assets
5,291
5,534
6,568
7,664
8,208
9,946
11,519
14,069
13,757
15,575
17,691
20,858
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
325
726
471
266
780
585
1,265
1,111
1,682
1,948
1,913
1,963
Investing
-235
205
-294
-351
-318
-737
-995
-1,433
120
-1,011
-1,288
-1,682
Financing
-52
-927
-138
85
-379
79
-272
380
-1,761
-1,145
-811
-503
Net Cash Flow
39
3
40
0
82
-73
-2
58
42
-207
-186
-222
Free Cash Flow
190
472
-163
-411
253
237
1,116
783
1,453
1,761
1,278
1,476
CFO/OP
101
107
73
47
92
59
86
73
121
105
96
86
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
52
42
46
62
62
72
66
65
67
65
69
74
Inventory Days
169
169
198
221
186
198
241
262
194
197
224
239
Days Payable
101
108
122
147
119
104
112
102
87
129
148
161
Cash Conversion Cycle
121
103
122
135
129
167
196
225
174
132
145
152
Working Capital Days
-52
13
34
40
55
44
48
31
66
135
123
123
ROCE %
12%
23%
21%
17%
16%
18%
22%
18%
14%
20%
20%
21%

Shareholding Pattern

As of Jun 2026
Promoters 49.70%
DIIs 22.63%
Public 17.04%
FIIs 10.42%
Others 0.21%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
60.16%
58.84%
58.84%
57.13%
57.13%
57.14%
57.16%
57.16%
57.16%
57.16%
56.74%
56.74%
56.74%
56.38%
55.66%
55.66%
55.13%
53.04%
51.20%
51.20%
51.20%
49.70%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
9.11%
8.69%
9.02%
10.15%
9.41%
9.11%
9.48%
9.97%
10.16%
10.42%
DIIs
12.97%
14.28%
13.78%
13.76%
13.93%
13.88%
15.26%
16.44%
16.69%
15.43%
17.64%
14.94%
15.63%
18.57%
19.21%
18.01%
19.42%
21.80%
21.93%
21.54%
21.40%
22.63%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
21.75%
21.70%
21.15%
22.85%
22.63%
22.33%
22.28%
21.74%
21.44%
20.61%
19.36%
18.60%
18.31%
16.15%
15.84%
15.90%
15.77%
15.69%
17.18%
17.09%
17.06%
17.04%
Others
5.12%
5.17%
6.23%
6.26%
6.31%
6.65%
5.30%
4.67%
4.71%
6.80%
6.26%
9.72%
0.21%
0.21%
0.26%
0.28%
0.28%
0.36%
0.22%
0.21%
0.19%
0.21%
No. of Shareholders
92,594
93,540
87,392
86,881
81,869
84,104
79,721
76,516
73,440
66,790
69,442
65,184
65,830
69,627
74,744
84,038
84,326
79,740
67,196
64,536
62,835
62,822

Documents

1
Concall - Jun 2020 Jun 2020
2
Concall - Feb 2018 Feb 2018
3
Concall - Jun 2020 Jun 2020
4
Concall - Aug 2020 Aug 2020
5
Concall - Jun 2026 Jun 2026

Frequently Asked Questions about Alkem Laboratories Ltd

What does Alkem Laboratories Ltd do?
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
Where is Alkem Laboratories Ltd (ALKEM) listed?
Alkem Laboratories Ltd is listed on the Indian stock exchanges. It is listed on NSE: ALKEM and BSE: 539523. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Alkem Laboratories Ltd belong to?
Alkem Laboratories Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Alkem Laboratories Ltd?
Alkem Laboratories Ltd has a market capitalisation of approximately ₹65473.79 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Alkem Laboratories Ltd?
The Price-to-Earnings (PE) ratio of Alkem Laboratories Ltd is 30.34. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Alkem Laboratories Ltd?
Over the past 52 weeks, Alkem Laboratories Ltd has traded between a low of ₹5,075 and a high of ₹5,933.5. This range helps investors understand the stock's price volatility and recent trading levels.
Does Alkem Laboratories Ltd pay dividends?
Yes, Alkem Laboratories Ltd has a dividend yield of 0.99%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Alkem Laboratories Ltd?
Alkem Laboratories Ltd has a Return on Equity (ROE) of 16.40%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Alkem Laboratories Ltd on Tapetide?
On Tapetide, you can view Alkem Laboratories Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)

Website alkemlabs.com
CEO Mr. Basudeo Narian Singh
Employees 18,785
Listed 2015-12-23
Face Value ₹ 2
Issued Size 11,95,65,000

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List